LONDON--(BUSINESS WIRE)--The market for antibiotic resistance is increasingly gaining prominence from pole to pole. This is especially evident in such countries as China, the USA and Kuwait. In the USA, medical costs associated with drug-resistant infections are evaluated at about USD 19.8 billion on an annual basis. On a regional scale, Europe, for instance, accounts for over 23,000 deaths caused by antibiotic-resistant infections annually.
Increasing resistance to drugs of bacteria together with the limited number of new antibiotics being approved has befogged future outlook for the healthcare market. Despite recent approval of several antibiotics, many drugs available on the market were established long ago and are no more effective for a raft of infections. However, at present there are over 105 antibiotics on different stages of development. This shows that market players start concentrating on R&D activities.
Discounted market research report “Antibiotic Resistance 2012: The Antibiotics Development Pipeline and Strategies to Combat Antibiotic Resistance” worked out by Biopharm Reports is a source of the unique data on the antibiotic resistance market, antibiotics development pipeline as well as strategies aimed at overcoming antibiotic resistance. The study delves deep into past and current trends of the antibiotic resistance market, examines marketed and pipeline antibiotics. Information on market players and detailed discussion of various market segments can be found in the report.
Report Details:
Title: Antibiotic Resistance 2012: The Antibiotics Development Pipeline and Strategies to Combat Antibiotic Resistance
Published: August, 2012
Pages: 118
Price: US$ 2,997.00 US$ 2,097.00
Report Contents:
EXECUTIVE SUMMARY
CHAPTER 1 INTRODUCTION
1.1 Antibiotic Resistance
1.2 Resistance Mechanisms
1.3 The Resistome
1.4 Pathogenomics
1.5 Strategies and Targets
1.6 The Cost of Antibiotic Resistance
1.7 Global Surveillance
1.8 This Report
CHAPTER 2 ANTIBIOTIC RESISTANCE, GLOBAL TRENDS
2.1 Antibiotic Resistance
2.2 Europe
2.2.1 Carbapenem-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa (2005 to 2010)
2.2.2 Escherichia coli
2.2.3 Streptococcus pneumoniae
2.2.4 Staphylococcus aureus
2.2.5 Enterococcus faecalis
2.2.6 Klebsiella pneumoniae
2.2.7 Pseudomonas aeruginosa
2.3 Other Countries
2.4 China
2.5 USA
2.6 Kuwait
2.7 Discussion
CHAPTER 3 MARKETED ANTIBIOTICS
3.1 Marketed Antibiotics
…
More market research reports by Biopharm Reports can be found at http://marketpublishers.com/members/biopharm_reports/info.html